Loading
A phase 3 trial of Futibatinib, Zimberelimab, Durvalumab, Pembrolizumab, Gemcitabine and Cisplatin in biliary tract cancer, run by Taiho Pharmaceutical Co., Ltd., now recruiting.
Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer is a phase 3 interventional study registered as NCT07710885 by Taiho Pharmaceutical Co., Ltd., with 784 participants planned, started 2026-06-24 and due to reach its primary completion in 2030-04-30. Interventions recorded: Futibatinib, Zimberelimab, Durvalumab, Pembrolizumab, Gemcitabine and Cisplatin.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Araris Biotech (Taiho), Futibatinib, Cisplatin, Pembrolizumab and the tag pipeline.
Shares Durvalumab, Gemcitabine, Biliary tract cancer (cholangiocarcinoma), Platinum agents and the tag pipeline.
Shares Durvalumab, Gemcitabine, Biliary tract cancer (cholangiocarcinoma), Platinum agents and the tag pipeline.
Shares Gemcitabine, Biliary tract cancer (cholangiocarcinoma), Platinum agents, Cisplatin and the tag pipeline.
Shares Durvalumab, Gemcitabine, Platinum agents, Cisplatin and the tag pipeline.
Shares Durvalumab, Gemcitabine, Biliary tract cancer (cholangiocarcinoma), Cisplatin and the tag pipeline.
Shares Durvalumab, Platinum agents, Cisplatin, Pembrolizumab and the tag pipeline.
Shares Gemcitabine, Platinum agents, Cisplatin, Cytotoxic chemotherapy and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/